Vicapsys Life Sciences Completes Reverse Merger and NitroMist Acquisition

Key Facts

1Vicapsys Life Sciences completed a reverse merger with Stateline Distributors of Puerto Rico.

2The company signed a definitive agreement to acquire NitroMist for a $2.0 million convertible note.

3The company is in discussions to acquire a 120,000-square-foot former pharmaceutical manufacturing facility in Puerto Rico.

In a move reflecting a shift toward vertical integration in the pharmaceutical sector, Vicapsys Life Sciences has finalized a reverse merger with Puerto Rico-based Stateline Distributors. According to reports, the company has also entered into a definitive agreement to acquire NitroMist, an FDA-approved lingual aerosol, for a $2.0 million convertible note. Additionally, the firm is in active discussions to acquire a 120,000-square-foot pharmaceutical manufacturing facility to bolster its production capabilities.

The strategic expansion aims to leverage Stateline's distribution network to serve federal and underserved markets. Per market data, VICP stock closed at $0.35 on September 22, 2026, having traded within a range of $0.30 to $0.50 during that session. By securing both a distribution partner and an FDA-approved product, the company is positioning itself to control more of the pharmaceutical value chain through established federal contracting channels.

Traders should watch for the formal conclusion of talks regarding the manufacturing facility in Puerto Rico as a primary catalyst for operational scaling. With VICP at $0.35 (close September 22, 2026), the focus remains on the company's ability to transition its new assets into revenue-generating operations. Future updates regarding the integration of NitroMist into the company's portfolio will be critical for assessing long-term valuation.